Figure 2. Vaccine Efficacy in Pre-exposure and Post-exposure Regimens.

[A] Dose Escalation: Cynomologous monkeys were vaccinated once with various doses (10⁹–10¹¹ vp) of the AdC68rab.gp vector, a control AdC68 vector given at 10¹¹ vp, or three doses of commercial human raies vaccine, HDCV. Additional control animals received PBS only. Animals were challenged with canine rabies vius at 18 weeks after AdC68 vaccination. [B] Effect of pre-existing HAd-V5 neutralizing antibodies: Groups of monkeys were injected with 10¹² vp of an AdHu5 vector expressing a reporter protein, or they were left untreated.. Four weeks later, pre-treated, as well as untreated animals, were vaccinated with 10¹⁰ vp of AdC68rab.gp. A positive control group received commercial human rabies vaccine, HDCV given 3 times, a negative control group received PBS. Animals were challenged with canine rabies virus 18 weeks after AdC vaccination and survival was recorded. [C] Post-exposure prophylaxis: Nonhuman primates were infected with canine rabies virus. Six hours later, one group was vaccinated with 10¹⁰ vp of AdC68rab.gp and received commercial HRIG infiltrated at the rabies virus inoculation site. An additional group was vaccinated with AdC68rab.gp, but without HRIG. A positive control group was treated with the traditional vaccine regimen, i.e., HRIG combined with 4 doses of commercial PCEC human rabies vaccine, the latter given on days 1, 8, 15 and 29 relative to challenge. Additional control groups only received HRIG, a control AdC68 vector or PBS. Survival was recorded. [NB: need to change the vaccine in @C from HDCV to PCEC.

Graphs A–C show percent of animals that survived without developing signs of rabies. Numbers of animals per group are shown within each graph above the bars.